查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1861430

動物血漿製品及衍生市場（依動物種類、衍生類型、最終用戶及應用分類）－2025-2032年全球預測

Animal Blood Plasma Products & Derivatives Market by Animal Type, Derivative Type, End-User, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，動物血漿製品及衍生市場規模將達到 27.9 億美元，複合年成長率為 7.90%。

關鍵市場統計數據
基準年 2024 15.2億美元
預計年份：2025年 16.3億美元
預測年份 2032 27.9億美元
複合年成長率 (%) 7.90%

針對動物血漿製品及其衍生的全面指南，為多學科相關人員明確科學、監管和供應鏈方面的優先事項。

動物血漿製品及其衍生與生命科學、食品加工、獸醫學和工業生物技術等領域密切相關，需要從技術、監管和商業性等多個觀點進行綜合考慮。本執行摘要系統地評估了該領域的當前趨勢，檢驗了影響競爭力和營運重點的因素，包括產品衍生、終端應用和供應鏈特徵。分析從血清和纖維蛋白原等生物原料入手，逐步深入到從細胞培養到營養補充劑等下游應用，並將這些原料置於傳統和新興價值鏈中進行探討。

本導言強調了相關人員需要在科學嚴謹性和供應鏈彈性之間取得平衡。籌資策略的轉變、生物醫學和食品級衍生品質期望的不斷提高以及需求的跨領域性，凸顯了綜合決策的重要性。因此，本報告著重提供實際可行的見解，以協調實驗室需求、法規遵循和商業性需求，幫助企業優先投資於品質保證、供應商關係和特定應用產品開發。

技術進步、不斷變化的生物安全期望和永續性壓力如何共同作用，重塑該行業的採購、產品一致性和供應商整合。

近年來，主要受技術和政策驅動的趨勢，已導致供應商、製造商和終端用戶對待動物血漿衍生產品的方式發生變革性變化。細胞培養技術和組織工程平台的進步提高了對高品質血清和白蛋白的需求，促使供應商投資於可追溯性系統和更完善的品管流程。同時，加工和分離技術的創新提高了免疫球蛋白和纖維蛋白原製劑的一致性，使其在生物醫學研究和特定工業應用中得到更廣泛的應用。

不斷變化的法規正在重塑採購和檢驗實踐。更嚴格的文件要求和生物安全期望提升了供應商審查和原產地保證的重要性，尤其是在涉及人類健康的應用領域。同時，永續性考量正在推動上游工程採購和廢棄物管理的變革，鼓勵採用閉合迴路實踐和替代籌資策略。這些協同效應正在推動供應商組合的重組，並促使尋求確保和品管的企業進行垂直整合。因此，那些將研發重點與供應商能力和監管前瞻性相結合的企業，能夠在最大限度地減少營運中斷的同時，抓住新興技術機會。

了解 2025 年關稅調整如何重塑依賴特殊生物成分的組織的採購、供應商多元化和庫存策略。

2025年美國關稅調整和貿易政策轉變對整個供應鏈產生了重大影響，改變了依賴動物血漿衍生物企業的成本結構、供應商選擇和庫存策略。進口商和下游製造商正在透過重新評估採購區域、加快供應商多元化計劃以及盡可能優先選擇近岸生產來應對這些變化。這些戰術性應對措施也導致了營運方面的改變，例如延長供應商資格認證期限和擴大品質保證測試範圍，以確保符合監管和客戶規範。

關稅環境也影響商業談判和合約條款，買家尋求更彈性價格設定，供應商則希望簽訂更長期的協議以穩定收入。物流模式也正在做出相應調整，企業重新分配區域配送中心的庫存緩衝，以減少潛在的海關延誤和成本波動。對於血清和特殊蛋白質的技術使用者而言，採購部門在平衡供應安全和成本控制的同時，也越來越優先考慮具有本地生產能力的成熟供應商。整體而言，關稅環境凸顯了供應鏈透明度、冗餘性和合約彈性對於維持檢驗時限和生產連續性的重要性。

透過深度細分分析，將動物來源、衍生特性、終端用戶合規性和多樣化應用聯繫起來，以製定客製化的採購和研發策略。

細分市場分析揭示了不同動物種類、衍生產品類型、最終用戶和應用領域之間的差異化動態，這些差異對供應鏈設計和產品開發有著不同的影響。就動物種類（禽類、牛、羊、豬）而言，原料供應、病原體篩檢程序以及文化和監管偏好等方面的差異會影響特定應用領域對原料的選擇。例如，某些大批量應用會優先選擇牛產品，而不同的功能特性則會導致選擇豬源或羊源原料。同時，對牛、纖維蛋白原、免疫球蛋白、血清白蛋白和凝血酶等衍生產品類型的檢驗表明，每種衍生都有其獨特的加工、穩定性和品質保證要求，這些要求會影響儲存、處理和最終用途檢驗。

透過比較食品製造商、製藥公司和獸醫護理等終端用戶群體，可以發現他們在合規框架和績效預期方面存在差異。食品加工商強調食品安全認證和過敏原管理，製藥公司優先考慮可追溯性和監管文件，而獸醫使用者則需要在療效、成本和保存期限之間取得平衡。基於應用領域的差異（動物飼料、生物醫學研究、細胞培養基、食品加工、營養保健品、寵物食品產業、藥品和化妝品、組織工程）也反映在純度、功能規格和價值實現方面的差異。例如，生物醫學研究和細胞培養需要嚴格的批次間一致性和污染控制，而動物飼料和寵物食品應用則允許更廣泛的規格範圍，同時要求經濟高效的供應。整合這些細分觀點，有助於相關人員制定既能反映技術限制又能體現商業性優先事項的採購、品管和產品開發藍圖。

美洲、歐洲、中東和非洲以及亞太地區的區域動態和物流現實決定供應的連續性、合規性和供應商選擇。

區域性洞察揭示了地緣政治、物流和監管因素如何影響動物血漿衍生的獲取，並影響生產者和消費者的策略選擇。在美洲，接近性主要生物技術群聚和成熟的畜牧生產體系，為科研級和工業應用提供了強大的供應鏈支援。該地區擁有完善的低溫運輸物流基礎設施和法律規範，促進了區域內的跨境貿易。歐洲、中東和非洲地區（EMEA）的情況則較為複雜，某些司法管轄區擁有嚴格的管理體制，而有些司法管轄區則擁有新興的生產能力。這要求企業調整其合規策略，並投資與當地供應商建立夥伴關係，以確保產品品質和供應的連續性。

亞太地區正日益成為一個重要的樞紐，它融合了大規模的動物生產能力​​以及不斷發展的生物製造和研究。該地區的物流規模和成本效益為全球企業帶來了許多優勢，但採購者必須應對各地不同的監管環境和品質保證標準。在所有地區，當地的監管要求、運輸基礎設施和動物來源的可用性都會影響採購決策和策略供應商合作。因此，能夠分析區域優勢並結合特定應用需求的企業，將更有利於最佳化供應連續性、縮短前置作業時間並管理合規風險。

競爭定位和供應商策略突顯了專業知識、品質投資和夥伴關係模式，這些因素決定了能否獲得高純度、大批量的衍生物。

主要企業之間的競爭趨勢揭示了其不同的策略方針。有些企業專注於高純度生物醫學應用衍生的專業技術，而有些企業則強調食品和飼料產業的規模化和成本效益。市場地位受到企業在品質保證系統、生物安全認證和供應鏈可追溯性解決方案方面的投資的影響，這些投資旨在滿足受監管的終端用戶需求。投資於專有加工技術和嚴格檢驗通訊協定的企業，對需要可重複性和文件記錄的製藥和組織工程客戶而言，變得越來越有吸引力。

策略聯盟和契約製造關係也是競爭優勢的建構要素。那些將前端流程整合到附加價值服務（例如定製配方協助、法規文件支援和應用特定測試）中的公司，往往能夠與研究機構和專業製造商建立互惠互利的合作關係。同時，專注於大宗商品級衍生產品的生產商則利用其規模優勢和成本控制，在飼料和寵物食品等大宗應用市場中保持市場佔有率。透過觀察這些多元化的策略，相關人員可以根據自身業務需求評估潛在供應商，並優先選擇那些能夠滿足產品規格、合規要求和長期可靠性要求的合作夥伴。

為領導者提供切實可行的、優先考慮的行動方案，以加強供應鏈、整合研發和採購，並透過有針對性的供應商和產品策略創造價值。

產業領導者應實施一系列切實可行的措施，以增強韌性，使研發重點與供給能力相匹配，並在各種應用領域創造價值。首先，投資於整合原產地檢驗、生物安全審核和分析檢驗的供應商合格框架，將降低下游風險，並加快受監管應用領域的品質保證速度。其次，透過地理和物種多元化供應商網路，可以獲得具有特定功能特性的衍生，同時降低單點故障風險。第三，透過供應商協作測試和技術轉移通訊協定，將採購與研發連結起來，將加速產品開發，並確保實驗室規模的性能能夠轉化為生產規模的可靠性。

此外，企業應制定適應性強的合約模式，在價格穩定性和品質及數量調整的靈活性之間取得平衡，並採用反映應用關鍵性而非統一庫存規則的庫存策略。對於產品開發人員而言，優先開發能夠適應盡可能廣泛原料差異的配方，可以降低對供應商差異的依賴。最後，積極與監管機構和標準制定機構溝通，影響並預測合規要求，可以縮短產品上市時間並減少返工。透過落實這些建議，企業可以將這些洞察轉化為具有韌性的採購、穩健的產品平臺和永續的競爭優勢。

採用嚴謹的多方法研究途徑，結合相關人員訪談、技術整合和供應鏈分析，以產生經實務驗證的營運建議。

這些研究結果所依據的調查方法結合了關鍵相關利益者對話、技術文獻綜述和供應鏈分析，以確保為可操作的建議提供堅實的證據基礎。關鍵對話包括與來自食品、製藥和動物醫藥行業的採購經理、研發經理和品質保證專業人員進行結構化訪談，從而獲得關於採購限制、品質期望和物流實際情況的第一手觀點。作為這些對話的補充，研究人員還查閱了技術文獻和行業指南，以明確衍生產品的特定加工要求以及與各種最終用途相關的生物安全注意事項。

為識別通用瓶頸和提升韌性的關鍵因素，我們開展了供應鏈映射和貿易流量分析，重點關注低溫運輸要求、跨境合規性和供應商集中度。透過對定性資訊和營運指標進行三角驗證，我們制定了切實可行的建議，重點是供應商資格認證、合約設計和庫存管理。我們透過記錄假設、從多個相關人員的觀點檢驗結果以及確保分析過程的透明度，從而保證了調查方法的嚴謹性，並增強了研究結果對實踐者的可複製性和可信度。

策略整合，重點在於檢驗、來源多元化和跨職能協作，以確保複雜生物供應鏈的韌性和技術性能。

摘要，動物血漿製品及其衍生兼具科學複雜性和操作敏感性，需要採取綜合策略來管理品質、合規性和連續性。加工和應用科學的進步提高了人們對可追溯性和批間一致性的期望，而監管和貿易趨勢則凸顯了多元化和靈活採購實踐的重要性。積極主動地將嚴格的供應商篩選、策略性的地域多元化以及研發和採購部門之間的協作相結合的相關人員，將更有能力降低風險並抓住生物醫學、食品和獸醫領域的機會。

最終，該行業將獎勵那些將生物材料視為更廣泛的產品和研究生態系統中關鍵組成部分，而不是僅僅將其視為商品的機構。透過投資檢驗、發展策略供應商關係以及將監管前瞻性納入採購決策，機構可以確保營運韌性，並維持支持最終用戶信心和創新所需的技術性能。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 噴霧乾燥豬血漿的應用正在迅速擴展，透過調節斷奶仔豬的腸道環境來改善其健康狀況。
  • 在歐洲獲得監管部門批准，在寵物食品中添加牛血漿蛋白（以增強免疫力和促進消化）。
  • 採用先進的超過濾和層析法技術提高動物血漿中免疫球蛋白的純度
  • 血漿處理公司與生技公司進行策略合作，共同開發畜牧業的治療性免疫球蛋白產品。
  • 亞太地區對噴霧乾燥設施的投資正在增加，以確保高品質動物血漿衍生產品的本地供應。
  • 區塊鏈溯源平台的出現，用於檢驗動物血漿原料的永續來源
  • 整合紫外線和伽馬射線等病原體去活化技術，以提高等離子體衍生飼料原料的安全性
  • 開發源自動物血漿的新型生物活性胜肽組成，並將其應用於功能性水產飼料，以改善魚類健康。
  • 消費者對優質寵物食品配方中非基因改造、經認證的血漿蛋白的需求日益成長，以滿足潔淨標示的要求。
  • 非洲豬瘟疫情對全球豬血漿供應鏈的影響：價格波動與採購挑戰

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依動物類型分類的動物血漿製品及衍生市場

  • 鳥類
  • 牛
  • 羊
  • 豬

9. 依衍生物類型分類的動物血漿製品及衍生市場

  • 牛
  • 纖維蛋白原
  • 免疫球蛋白
  • 血清白蛋白
  • 凝血酶

第10章 依最終用戶分類的動物血漿製品及衍生市場

  • 食品製造商
  • 製藥公司
  • 獸醫

第11章 動物血漿製品及衍生市場（依應用領域分類）

  • 動物飼料
  • 生物醫學研究
  • 細胞培養基
  • 食品加工
  • 營養補充品
  • 寵物食品業
  • 藥品和化妝品
  • 組織工程

第12章 各地區動物血漿製品及衍生市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 依組別分類的動物血漿製品及衍生市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國動物血漿製品及衍生市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • ACROBiosystems Inc.
    • Alfa Laval Corporate AB
    • ANZCO Foods Limited
    • Auckland BioSciences Ltd.
    • BioChemed Services
    • Biowest Company
    • Bovogen Biologicals Pty Ltd.
    • Canvax Reagents SL
    • Ebrator Biochemicals Inc.
    • Kraeber & Co. GmbH
    • Lake Immunogenics, Inc.
    • LAMPIRE Biological Laboratories, Inc.
    • Meiji Holdings Co., Ltd.
    • Merck KGaA
    • Pel-Freez, LLC
    • Rockland Immunochemicals, Inc.
    • Rocky Mountain Biologicals
    • Scripps Laboratories, Inc.
    • Sigma-Aldrich
    • TCS Biosciences Ltd.
    • Thermo Fisher Scientific Inc.
Product Code: MRR-69324464D0E2

The Animal Blood Plasma Products & Derivatives Market is projected to grow by USD 2.79 billion at a CAGR of 7.90% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.52 billion
Estimated Year [2025] USD 1.63 billion
Forecast Year [2032] USD 2.79 billion
CAGR (%) 7.90%

A comprehensive orientation to animal blood plasma products and derivatives that clarifies scientific, regulatory, and supply chain priorities for interdisciplinary stakeholders

The animal blood plasma products and derivatives landscape intersects life sciences, food processing, veterinary care, and industrial biotechnology, demanding a synthesis of technical, regulatory, and commercial perspectives. This executive summary introduces a structured appraisal of the sector's current dynamics, examining product derivatives, end-use applications, and supply chain characteristics that together shape competitive and operational priorities. By framing the conversation around biological inputs such as serum and fibrinogen as well as downstream applications spanning cell culture and nutrition, the analysis situates these materials within both traditional and emerging value chains.

This introduction highlights the necessity for stakeholders to balance scientific rigor with supply chain agility. Shifts in sourcing strategies, evolving quality expectations for biomedical and food-grade derivatives, and the cross-sectoral nature of demand underscore the importance of integrated decision-making. Consequently, the report emphasizes practical insights that align laboratory needs, regulatory compliance, and commercial imperatives, enabling organizations to prioritize investments in quality assurance, supplier relationships, and application-specific product development.

How technological advances, evolving biosafety expectations, and sustainability pressures are jointly reshaping sourcing, product consistency, and supplier integration in the sector

Recent developments have triggered transformative shifts in how suppliers, manufacturers, and end-users approach animal blood plasma derivatives, with technology and policy acting as primary accelerants. Advances in cell-culture techniques and tissue-engineering platforms have increased demand for high-quality serum and albumin, prompting suppliers to invest in traceability systems and enhanced quality control processes. Concurrently, innovations in processing and fractionation have improved the consistency of immunoglobulin and fibrinogen preparations, enabling wider adoption in both biomedical research and specialized industrial uses.

Regulatory evolution is reshaping procurement and validation approaches. Stricter documentation and biosafety expectations have elevated the importance of supplier vetting and provenance assurance, especially for applications with human-health implications. In parallel, sustainability considerations are prompting upstream changes in sourcing and waste management, incentivizing closed-loop practices and alternative sourcing strategies. These converging forces are driving a reconfiguration of supplier portfolios and encouraging vertical integration by firms seeking to secure raw materials and control quality. As a result, organizations that align R&D priorities with supplier capability and regulatory foresight are positioning themselves to capitalize on emerging technical opportunities while mitigating operational disruption.

Understanding how 2025 tariff adjustments reshaped procurement, supplier diversification, and inventory strategies for organizations dependent on specialized biological inputs

Tariff adjustments and trade policy shifts in the United States for 2025 have had material implications across the supply chain, altering cost structures, supplier selection, and inventory strategies for businesses reliant on animal blood plasma derivatives. Importers and downstream manufacturers have responded by reassessing sourcing geographies, accelerating supplier diversification plans, and increasing emphasis on nearshoring where feasible. These tactical responses have been accompanied by operational changes such as extended supplier qualification timelines and expanded quality assurance testing to ensure conformity with both regulatory and customer specifications.

The tariff environment has also influenced commercial negotiations and contractual terms, with buyers seeking more flexible pricing arrangements and suppliers negotiating longer-term contracts to stabilize revenue streams. Logistic patterns have adjusted in response, with companies reallocating inventory buffers across regional distribution centers to mitigate potential customs delays and cost volatility. For technology-driven users of serum and specialized proteins, procurement teams are balancing the need for high-certainty supply with cost management, often prioritizing validated suppliers with regional production capabilities. Overall, the tariff context has increased the premium on supply chain transparency, redundancy, and contractual agility to sustain research timelines and production continuity.

Deep segmentation insights that connect animal source, derivative characteristics, end-user compliance, and diverse applications to inform tailored sourcing and R&D strategies

Segmentation analysis reveals differentiated dynamics when observed through the lenses of animal type, derivative type, end-user, and application, each offering distinct implications for supply chain design and product development. When considering animal type-Avian, Bovine, Ovine, and Porcine-differences in source availability, pathogen screening protocols, and cultural or regulatory preferences influence which raw materials are favored for specific applications, with bovine-derived products commonly prioritized for certain high-volume applications and porcine or ovine materials selected where functional properties differ. In parallel, examining derivative types such as Fetal Bovine Serum, Fibrinogen, Immunoglobulin, Serum Albumin, and Thrombin clarifies that each derivative carries unique processing, stability, and quality assurance requirements that affect storage, handling, and end-use validation.

End-user segmentation across Food Manufacturers, Pharmaceutical Companies, and Veterinary sectors highlights divergent compliance frameworks and performance expectations: food processors emphasize food-safety certifications and allergen control, pharmaceutical firms prioritize traceability and regulatory documentation, and veterinary users balance efficacy with cost and shelf-life considerations. Application-driven distinctions-spanning Animal Feed, Biomedical Research, Cell Culture Media, Food Processing, Nutrition Supplements, Pet Food Industry, Pharmaceuticals & Cosmetics, and Tissue Engineering-illustrate variation in purity, functional specification, and value capture. For instance, biomedical research and cell culture demand stringent lot-to-lot consistency and contamination controls, while applications in animal feed and pet food tolerate broader specification ranges but require cost-efficient supply. Integrating these segmentation perspectives enables stakeholders to tailor sourcing, quality management, and product development roadmaps that reflect both technical constraints and commercial priorities.

Regional dynamics and logistical realities across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine supply continuity, compliance, and supplier choice

Regional insights illuminate how geopolitical, logistical, and regulatory factors shape access to animal blood plasma derivatives and influence strategic choices by producers and consumers. In the Americas, proximity to major biotech clusters and established animal agriculture systems supports robust supply chains for both research-grade and industrial applications, with infrastructure geared toward cold-chain logistics and regulatory oversight that facilitates cross-border trade within the region. Europe, Middle East & Africa presents a complex mosaic where stringent regulatory regimes in certain jurisdictions coexist with emerging production capacity in others, prompting companies to adapt compliance strategies and invest in regional supplier partnerships to assure quality and continuity.

Asia-Pacific has become increasingly pivotal, combining large-scale animal production capacity with expanding biomanufacturing and research activity. This region's logistical scale and cost efficiencies can offer advantages to global firms, though buyers must navigate heterogeneous regulatory landscapes and varying quality assurance norms. Across all regions, regional regulatory expectations, transport infrastructure, and source animal availability drive procurement decisions and strategic supplier alignment. Consequently, organizations that map regional strengths against application-specific requirements are better positioned to optimize supply continuity, reduce lead times, and manage compliance risk.

Competitive positioning and supplier strategies that delineate specialization, quality investment, and partnership models shaping access to high-purity and large-volume derivatives

Competitive dynamics among key companies reveal differentiated strategic approaches, with some firms focusing on specialization in high-purity derivatives for biomedical applications while others emphasize scale and cost-efficiency for food and feed segments. Market positions are influenced by investments in quality assurance systems, biosafety certifications, and supply chain traceability solutions that respond to the demands of regulated end-users. Organizations investing in proprietary processing technologies and rigorous validation protocols are increasingly attractive to pharmaceutical and tissue-engineering customers that require reproducibility and documentation.

Strategic partnerships and contract manufacturing relationships also shape competitive advantage. Firms that integrate forward into value-added services-such as custom formulation support, regulatory dossier assistance, and application-specific testing-tend to capture higher-margin relationships with research institutions and specialty manufacturers. Meanwhile, producers focused on commodity-grade derivatives leverage scale and cost management to maintain relevance in large-volume applications like animal feed and pet food. Observing these varied strategies enables stakeholders to benchmark potential suppliers against operational needs and to prioritize partners whose capabilities align with product specifications, compliance requirements, and long-term reliability.

Practical and prioritized actions for leaders to fortify supply chains, synchronize R&D with procurement, and capture value through targeted supplier and product strategies

Industry leaders must adopt a set of pragmatic, actionable steps to strengthen resilience, align R&D priorities with supply capabilities, and capture value across applications. First, investing in supplier qualification frameworks that integrate provenance verification, biosafety audits, and analytical validation will reduce downstream risk and shorten time-to-assurance for regulated applications. Second, diversifying supplier networks geographically and across animal sources can mitigate exposure to single-point disruptions while enabling access to derivatives with specific functional properties. Third, aligning procurement and R&D teams through joint supplier trials and technical transfer protocols will accelerate product development and ensure that laboratory-scale performance translates into production-scale reliability.

Additionally, companies should develop adaptive contracting approaches that balance price stability with flexibility for quality and volume adjustments, and they should incorporate inventory strategies that reflect application criticality rather than uniform stocking rules. For product developers, prioritizing formulations that accommodate broader input variability where possible will reduce sensitivity to supplier fluctuation. Finally, engaging proactively with regulators and standard-setting bodies to influence or anticipate compliance requirements will yield advantages in time-to-market and reduce rework. By operationalizing these recommendations, organizations can transform insight into resilient procurement, robust product pipelines, and sustained competitive differentiation.

A rigorous, multi-method research approach combining stakeholder interviews, technical synthesis, and supply chain mapping to generate validated operational recommendations

The research methodology underpinning these insights combines primary stakeholder engagement, technical literature synthesis, and supply chain analysis to ensure a robust evidence base that supports actionable recommendations. Primary engagement included structured interviews with procurement leads, R&D heads, and quality assurance professionals across food, pharmaceutical, and veterinary organizations, providing firsthand perspectives on sourcing constraints, quality expectations, and logistical realities. Complementing these dialogues, a review of technical literature and industry guidelines clarified derivative-specific processing requirements and biosafety considerations relevant to different end uses.

Supply chain mapping and trade-flow analysis were conducted to identify common bottlenecks and resilience levers, with attention to cold-chain demands, cross-border compliance, and supplier concentration. Triangulation of qualitative inputs with operational indicators allowed for the development of pragmatic recommendations focused on supplier qualification, contractual design, and inventory management. Throughout, methodological rigor was maintained by documenting assumptions, validating findings through multiple stakeholder perspectives, and prioritizing transparency in analytic steps to support reproducibility and confidence in the implications drawn for practitioners.

A strategic synthesis that emphasizes validation, supplier diversification, and cross-functional alignment to ensure resilience and technical performance in complex biological supply chains

In summary, animal blood plasma products and derivatives occupy a nexus of scientific complexity and operational sensitivity that requires integrated strategies to manage quality, compliance, and continuity. Advances in processing and application science have elevated expectations for traceability and lot consistency, while regulatory and trade dynamics have amplified the need for diversified sourcing and agile procurement. Stakeholders who proactively combine rigorous supplier qualification, strategic geographic diversification, and alignment between research and procurement functions will better mitigate risk and seize opportunities across biomedical, food, and veterinary arenas.

Ultimately, the sector rewards organizations that treat biological inputs not merely as commodities but as critical components of broader product and research ecosystems. By investing in validation, fostering strategic supplier relationships, and embedding regulatory foresight into procurement decisions, institutions can ensure operational resilience and maintain the technical performance that underpins end-user trust and innovation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid expansion of spray-dried porcine plasma use to enhance post-weaning piglet performance through gut health modulation
  • 5.2. Regulatory clearance for bovine blood plasma protein inclusion in European pet food to boost immune function and digestion
  • 5.3. Adoption of advanced ultrafiltration and chromatography techniques to increase immunoglobulin purity from animal blood plasma
  • 5.4. Strategic collaborations between plasma processors and biotech firms to develop therapeutic immunoglobulin treatments for livestock
  • 5.5. Increasing investment in Asia-Pacific spray-drying facilities to secure local supply of high-quality animal plasma derivatives
  • 5.6. Emergence of blockchain-enabled traceability platforms for verifying sustainable sourcing of animal blood plasma raw materials
  • 5.7. Integration of pathogen inactivation technologies such as UV and gamma irradiation to enhance safety of plasma-based feed ingredients
  • 5.8. Development of novel bioactive peptide fractions from animal plasma for use in functional aquaculture feeds to improve fish health
  • 5.9. Rising consumer demand for non-GMO certified blood plasma proteins in premium pet food formulations to meet clean label requirements
  • 5.10. Impact of African swine fever outbreaks on global porcine plasma supply chains leading to price volatility and sourcing challenges

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Blood Plasma Products & Derivatives Market, by Animal Type

  • 8.1. Avian
  • 8.2. Bovine
  • 8.3. Ovine
  • 8.4. Porcine

9. Animal Blood Plasma Products & Derivatives Market, by Derivative Type

  • 9.1. Fetal Bovine Serum
  • 9.2. Fibrinogen
  • 9.3. Immunoglobulin
  • 9.4. Serum Albumin
  • 9.5. Thrombin

10. Animal Blood Plasma Products & Derivatives Market, by End-User

  • 10.1. Food Manufacturers
  • 10.2. Pharmaceutical Companies
  • 10.3. Veterinary

11. Animal Blood Plasma Products & Derivatives Market, by Application

  • 11.1. Animal Feed
  • 11.2. Biomedical Research
  • 11.3. Cell Culture Media
  • 11.4. Food Processing
  • 11.5. Nutrition Supplements
  • 11.6. Pet Food Industry
  • 11.7. Pharmaceuticals & Cosmetics
  • 11.8. Tissue Engineering

12. Animal Blood Plasma Products & Derivatives Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Animal Blood Plasma Products & Derivatives Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Animal Blood Plasma Products & Derivatives Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. ACROBiosystems Inc.
    • 15.3.2. Alfa Laval Corporate AB
    • 15.3.3. ANZCO Foods Limited
    • 15.3.4. Auckland BioSciences Ltd.
    • 15.3.5. BioChemed Services
    • 15.3.6. Biowest Company
    • 15.3.7. Bovogen Biologicals Pty Ltd.
    • 15.3.8. Canvax Reagents S.L.
    • 15.3.9. Ebrator Biochemicals Inc.
    • 15.3.10. Kraeber & Co. GmbH
    • 15.3.11. Lake Immunogenics, Inc.
    • 15.3.12. LAMPIRE Biological Laboratories, Inc.
    • 15.3.13. Meiji Holdings Co., Ltd.
    • 15.3.14. Merck KGaA
    • 15.3.15. Pel-Freez, LLC
    • 15.3.16. Rockland Immunochemicals, Inc.
    • 15.3.17. Rocky Mountain Biologicals
    • 15.3.18. Scripps Laboratories, Inc.
    • 15.3.19. Sigma-Aldrich
    • 15.3.20. TCS Biosciences Ltd.
    • 15.3.21. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY AVIAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY AVIAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY AVIAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY AVIAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY AVIAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY AVIAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY BOVINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY BOVINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY BOVINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY BOVINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY BOVINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY BOVINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY OVINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY OVINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY OVINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY OVINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY OVINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY OVINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PORCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PORCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PORCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PORCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PORCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PORCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FETAL BOVINE SERUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FETAL BOVINE SERUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FETAL BOVINE SERUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FETAL BOVINE SERUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FETAL BOVINE SERUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FETAL BOVINE SERUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FIBRINOGEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FIBRINOGEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FIBRINOGEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FIBRINOGEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FIBRINOGEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FIBRINOGEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY SERUM ALBUMIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY SERUM ALBUMIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY SERUM ALBUMIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY SERUM ALBUMIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY SERUM ALBUMIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY SERUM ALBUMIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY THROMBIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY THROMBIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY THROMBIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY THROMBIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY THROMBIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY THROMBIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FOOD MANUFACTURERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FOOD MANUFACTURERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FOOD MANUFACTURERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FOOD MANUFACTURERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FOOD MANUFACTURERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FOOD MANUFACTURERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY VETERINARY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY VETERINARY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY VETERINARY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY VETERINARY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY VETERINARY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY VETERINARY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL FEED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL FEED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL FEED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL FEED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL FEED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL FEED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY BIOMEDICAL RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY BIOMEDICAL RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY BIOMEDICAL RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY BIOMEDICAL RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY BIOMEDICAL RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY BIOMEDICAL RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY CELL CULTURE MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY CELL CULTURE MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY CELL CULTURE MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY CELL CULTURE MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY CELL CULTURE MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY CELL CULTURE MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FOOD PROCESSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FOOD PROCESSING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FOOD PROCESSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FOOD PROCESSING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FOOD PROCESSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FOOD PROCESSING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY NUTRITION SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY NUTRITION SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY NUTRITION SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY NUTRITION SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY NUTRITION SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY NUTRITION SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PET FOOD INDUSTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PET FOOD INDUSTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PET FOOD INDUSTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PET FOOD INDUSTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PET FOOD INDUSTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PET FOOD INDUSTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PHARMACEUTICALS & COSMETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PHARMACEUTICALS & COSMETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PHARMACEUTICALS & COSMETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PHARMACEUTICALS & COSMETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PHARMACEUTICALS & COSMETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PHARMACEUTICALS & COSMETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. LATIN AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. LATIN AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. MIDDLE EAST ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. MIDDLE EAST ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. MIDDLE EAST ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 192. MIDDLE EAST ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 194. MIDDLE EAST ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 195. AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 202. AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 203. AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 204. AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. ASEAN ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. ASEAN ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. ASEAN ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. ASEAN ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. ASEAN ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. ASEAN ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. ASEAN ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 224. ASEAN ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 225. ASEAN ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 226. ASEAN ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 227. GCC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GCC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GCC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. GCC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. GCC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. GCC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. GCC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 234. GCC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 235. GCC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 236. GCC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPEAN UNION ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPEAN UNION ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPEAN UNION ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPEAN UNION ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPEAN UNION ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 247. BRICS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. BRICS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. BRICS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. BRICS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. BRICS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. BRICS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. BRICS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 254. BRICS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 255. BRICS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 256. BRICS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 257. G7 ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. G7 ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. G7 ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. G7 ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. G7 ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. G7 ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. G7 ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 264. G7 ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 265. G7 ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. G7 ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 267. NATO ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. NATO ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. NATO ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. NATO ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. NATO ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. NATO A